RELiZORB^® is a digestive enzyme cartridge that connects to enteral tube feeding systems. It is designed to mimic normal pancreatic function by helping to break down the fats in enteral tube feeding formula. By breaking down these fats before the formula is ingested, RELiZORB^® may allow for delivery of increased absorbable calories and simplify the use of enzymes in overnight feedings. 

Status

RELiZORB^® is FDA-approved for people who are partially or completely unable to break down and absorb fats. Two studies to test the safety, tolerability and effectiveness of RELiZORB^® in people with CF have been completed.

Sponsor

This program was sponsored by Alcresta and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.

Recent Changes

7/25/2017

In July 2017, The U.S. Food and Drug Administration (FDA) approved the use of RELiZORB^® for children ages 5 to 18 who use a feeding tube. The FDA initially approved use of the enzyme cartridge for tube feeding for people ages 18 and over.